Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Gastroesophageal Junction Cancer Specialty Channel

Gastroesophageal Junction Cancer
Specialty Channel
FDA Approval
FDA Approves Zolbetuximab Plus Chemotherapy for Patients With HER2-Negative Gastric/Gastroesophageal Junction Adenocarcinoma With CLDN18.2-Positive Tumors
10/18/2024
Based on results from the SPOTLIGHT and GLOW trials, the FDA has approved first-line zolbetuximab plus fluoropyrimidine and platinum-containing chemotherapy for patients with locally advanced, unresectable, or metastatic HER2-negative gastric...
Based on results from the SPOTLIGHT and GLOW trials, the FDA has approved first-line zolbetuximab plus fluoropyrimidine and platinum-containing chemotherapy for patients with locally advanced, unresectable, or metastatic HER2-negative gastric...
Based on results from the...
10/18/2024
Oncology
Jennifer Eads, MD, Abramson Cancer Center
Videos
Perioperative Chemotherapy Improved Survival Among Patients With Esophageal Adenocarcinoma
06/20/2024
Jennifer Eads, MD
Jennifer Eads, MD, comments on the results from the ESOPEC trial, which found perioperative chemotherapy improved survival for patients with resectable esophageal adenocarcinoma when compared with neoadjuvant chemoradiation.
Jennifer Eads, MD, comments on the results from the ESOPEC trial, which found perioperative chemotherapy improved survival for patients with resectable esophageal adenocarcinoma when compared with neoadjuvant chemoradiation.
Jennifer Eads, MD, comments on...
06/20/2024
Oncology
News
Addition of Relatlimab to Nivolumab and Chemotherapy Did Not Improve Response Among Patients With Unresectable, Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer
05/23/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 2 RELATIVITY-060 study, the addition of relatlimab to nivolumab and chemotherapy did not improve objective response among patients with unresectable, locally advanced or metastatic gastric or...
According to results from the phase 2 RELATIVITY-060 study, the addition of relatlimab to nivolumab and chemotherapy did not improve objective response among patients with unresectable, locally advanced or metastatic gastric or...
According to results from the...
05/23/2024
Oncology
Anant Ramaswamy, MD, Tata Memorial Hospital
Videos
Addition of Docetaxel to FOLFOX/CAPOX Backbone Fails to Improve OS in Advanced GEJ/Gastric Cancer
01/20/2024
Anant Ramaswamy, MD, discusses results from the phase 3 DOC-GC study which explored the efficacy of docetaxel added to a FOLFOX/CAPOX backbone for patients with advanced GEJ and gastric cancers.
Anant Ramaswamy, MD, discusses results from the phase 3 DOC-GC study which explored the efficacy of docetaxel added to a FOLFOX/CAPOX backbone for patients with advanced GEJ and gastric cancers.
Anant Ramaswamy, MD, discusses...
01/20/2024
Oncology
Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center
Videos
Global Treatment of Gastric/GEJ Cancer with Durvalumab Plus FLOT
01/19/2024
Yelena Janjigian, MD, discussed the recent subgroup analysis from the MATTERHORN study, evaluating durvalumab plus FLOT for patients with gastric or gastroesophageal junction cancer.
Yelena Janjigian, MD, discussed the recent subgroup analysis from the MATTERHORN study, evaluating durvalumab plus FLOT for patients with gastric or gastroesophageal junction cancer.
Yelena Janjigian, MD, discussed...
01/19/2024
Oncology
Conference Coverage
Docetaxel Added to Doublet Regimen Does Not Improve Survival in Advanced GEJ/Gastric Cancers
01/18/2024
The addition of docetaxel to a doublet regimen containing 5-fluorouracil/capecitabine and oxaliplatin demonstrated no improvement in OS among patients with advanced gastroesophageal junction (GEJ) and gastric cancers, according to a phase 3...
The addition of docetaxel to a doublet regimen containing 5-fluorouracil/capecitabine and oxaliplatin demonstrated no improvement in OS among patients with advanced gastroesophageal junction (GEJ) and gastric cancers, according to a phase 3...
The addition of docetaxel to a...
01/18/2024
Oncology
Conference Coverage
Addition of Durvalumab to FLOT Improved Response Rates Among Patients with Gastric or Gastroesophageal Junction Cancer Across All Regional Subgroups
01/18/2024
The improvement to pCR among patients with GC/GEJC with durvalumab plus FLOT seen in the MATTERHORN study was found to be consistent across all regional subgroups.
The improvement to pCR among patients with GC/GEJC with durvalumab plus FLOT seen in the MATTERHORN study was found to be consistent across all regional subgroups.
The improvement to pCR among...
01/18/2024
Oncology
Conference Coverage
Thoracoscopic Esophagectomy As Standard Treatment for Patients With Thoracic Esophageal Squamous Cell Carcinoma
01/18/2024
Thoracoscopic esophagectomy was found to be non-inferior in terms of OS to conventional esophagectomy among patients with thoracic esophageal squamous cell carcinoma.
Thoracoscopic esophagectomy was found to be non-inferior in terms of OS to conventional esophagectomy among patients with thoracic esophageal squamous cell carcinoma.
Thoracoscopic esophagectomy was...
01/18/2024
Oncology
Conference Coverage
Tiragolumab in Combination With Atezolizumab And Chemotherapy Shows Promise Among Patients With Esophageal Squamous Cell Carcinoma
01/18/2024
According to results from the phase 3 SKYSCRAPER-08, tiragolumab plus atezolizumab and chemotherapy improved the progression-free survival and overall survival among patients with esophageal squamous cell carcinoma.
According to results from the phase 3 SKYSCRAPER-08, tiragolumab plus atezolizumab and chemotherapy improved the progression-free survival and overall survival among patients with esophageal squamous cell carcinoma.
According to results from the...
01/18/2024
Oncology
News
Pembrolizumab Plus Chemotherapy Approved for Patients With HER2-Negative Gastric or Gastroesophageal Junction Cancer
11/17/2023
On November 16, 2023, the FDA granted approval to pembrolizumab plus chemotherapy for the treatment of patients with locally advanced or metastatic HER2-negative gastric or gastroesophageal junction cancer in the first-line setting.
On November 16, 2023, the FDA granted approval to pembrolizumab plus chemotherapy for the treatment of patients with locally advanced or metastatic HER2-negative gastric or gastroesophageal junction cancer in the first-line setting.
On November 16, 2023, the FDA...
11/17/2023
Oncology
Kohei Shitara, MD, PhD, National Cancer Center Hospital East
Videos
Perioperative Pembrolizumab Plus Chemotherapy for Resectable Gastric or Gastroesophageal Junction Cancer
11/14/2023
In the KEYNOTE-585 study, perioperative pembrolizumab plus chemotherapy improved the pathological complete response among patients with locally advanced, resectable gastric or gastroesophageal (G/GEJ) cancer, but not the event-free survival.
In the KEYNOTE-585 study, perioperative pembrolizumab plus chemotherapy improved the pathological complete response among patients with locally advanced, resectable gastric or gastroesophageal (G/GEJ) cancer, but not the event-free survival.
In the KEYNOTE-585 study,...
11/14/2023
Oncology

News

Jennifer Eads, MD, Abramson Cancer Center
Videos
Perioperative Chemotherapy Improved Survival Among Patients With Esophageal Adenocarcinoma
06/20/2024
Jennifer Eads, MD
Jennifer Eads, MD, comments on the results from the ESOPEC trial, which found perioperative chemotherapy improved survival for patients with resectable esophageal adenocarcinoma when compared with neoadjuvant chemoradiation.
Jennifer Eads, MD, comments on the results from the ESOPEC trial, which found perioperative chemotherapy improved survival for patients with resectable esophageal adenocarcinoma when compared with neoadjuvant chemoradiation.
Jennifer Eads, MD, comments on...
06/20/2024
Oncology
News
Addition of Relatlimab to Nivolumab and Chemotherapy Did Not Improve Response Among Patients With Unresectable, Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer
05/23/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 2 RELATIVITY-060 study, the addition of relatlimab to nivolumab and chemotherapy did not improve objective response among patients with unresectable, locally advanced or metastatic gastric or...
According to results from the phase 2 RELATIVITY-060 study, the addition of relatlimab to nivolumab and chemotherapy did not improve objective response among patients with unresectable, locally advanced or metastatic gastric or...
According to results from the...
05/23/2024
Oncology
Anant Ramaswamy, MD, Tata Memorial Hospital
Videos
Addition of Docetaxel to FOLFOX/CAPOX Backbone Fails to Improve OS in Advanced GEJ/Gastric Cancer
01/20/2024
Anant Ramaswamy, MD, discusses results from the phase 3 DOC-GC study which explored the efficacy of docetaxel added to a FOLFOX/CAPOX backbone for patients with advanced GEJ and gastric cancers.
Anant Ramaswamy, MD, discusses results from the phase 3 DOC-GC study which explored the efficacy of docetaxel added to a FOLFOX/CAPOX backbone for patients with advanced GEJ and gastric cancers.
Anant Ramaswamy, MD, discusses...
01/20/2024
Oncology
Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center
Videos
Global Treatment of Gastric/GEJ Cancer with Durvalumab Plus FLOT
01/19/2024
Yelena Janjigian, MD, discussed the recent subgroup analysis from the MATTERHORN study, evaluating durvalumab plus FLOT for patients with gastric or gastroesophageal junction cancer.
Yelena Janjigian, MD, discussed the recent subgroup analysis from the MATTERHORN study, evaluating durvalumab plus FLOT for patients with gastric or gastroesophageal junction cancer.
Yelena Janjigian, MD, discussed...
01/19/2024
Oncology
Conference Coverage
Docetaxel Added to Doublet Regimen Does Not Improve Survival in Advanced GEJ/Gastric Cancers
01/18/2024
The addition of docetaxel to a doublet regimen containing 5-fluorouracil/capecitabine and oxaliplatin demonstrated no improvement in OS among patients with advanced gastroesophageal junction (GEJ) and gastric cancers, according to a phase 3...
The addition of docetaxel to a doublet regimen containing 5-fluorouracil/capecitabine and oxaliplatin demonstrated no improvement in OS among patients with advanced gastroesophageal junction (GEJ) and gastric cancers, according to a phase 3...
The addition of docetaxel to a...
01/18/2024
Oncology
Conference Coverage
Addition of Durvalumab to FLOT Improved Response Rates Among Patients with Gastric or Gastroesophageal Junction Cancer Across All Regional Subgroups
01/18/2024
The improvement to pCR among patients with GC/GEJC with durvalumab plus FLOT seen in the MATTERHORN study was found to be consistent across all regional subgroups.
The improvement to pCR among patients with GC/GEJC with durvalumab plus FLOT seen in the MATTERHORN study was found to be consistent across all regional subgroups.
The improvement to pCR among...
01/18/2024
Oncology
Conference Coverage
Thoracoscopic Esophagectomy As Standard Treatment for Patients With Thoracic Esophageal Squamous Cell Carcinoma
01/18/2024
Thoracoscopic esophagectomy was found to be non-inferior in terms of OS to conventional esophagectomy among patients with thoracic esophageal squamous cell carcinoma.
Thoracoscopic esophagectomy was found to be non-inferior in terms of OS to conventional esophagectomy among patients with thoracic esophageal squamous cell carcinoma.
Thoracoscopic esophagectomy was...
01/18/2024
Oncology
Conference Coverage
Tiragolumab in Combination With Atezolizumab And Chemotherapy Shows Promise Among Patients With Esophageal Squamous Cell Carcinoma
01/18/2024
According to results from the phase 3 SKYSCRAPER-08, tiragolumab plus atezolizumab and chemotherapy improved the progression-free survival and overall survival among patients with esophageal squamous cell carcinoma.
According to results from the phase 3 SKYSCRAPER-08, tiragolumab plus atezolizumab and chemotherapy improved the progression-free survival and overall survival among patients with esophageal squamous cell carcinoma.
According to results from the...
01/18/2024
Oncology
News
Pembrolizumab Plus Chemotherapy Approved for Patients With HER2-Negative Gastric or Gastroesophageal Junction Cancer
11/17/2023
On November 16, 2023, the FDA granted approval to pembrolizumab plus chemotherapy for the treatment of patients with locally advanced or metastatic HER2-negative gastric or gastroesophageal junction cancer in the first-line setting.
On November 16, 2023, the FDA granted approval to pembrolizumab plus chemotherapy for the treatment of patients with locally advanced or metastatic HER2-negative gastric or gastroesophageal junction cancer in the first-line setting.
On November 16, 2023, the FDA...
11/17/2023
Oncology
Kohei Shitara, MD, PhD, National Cancer Center Hospital East
Videos
Perioperative Pembrolizumab Plus Chemotherapy for Resectable Gastric or Gastroesophageal Junction Cancer
11/14/2023
In the KEYNOTE-585 study, perioperative pembrolizumab plus chemotherapy improved the pathological complete response among patients with locally advanced, resectable gastric or gastroesophageal (G/GEJ) cancer, but not the event-free survival.
In the KEYNOTE-585 study, perioperative pembrolizumab plus chemotherapy improved the pathological complete response among patients with locally advanced, resectable gastric or gastroesophageal (G/GEJ) cancer, but not the event-free survival.
In the KEYNOTE-585 study,...
11/14/2023
Oncology
News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
Nirav Shah, MD
Videos
Innovation and the Future Development of Cell Therapies for Patients With B-Cell Lymphomas
08/05/2024
At the 2024 Pan Pacific Lymphoma Conference, Nirav Shah, MD, discusses innovation and the future development of cell therapies for patients with various types of B-cell malignancies.
At the 2024 Pan Pacific Lymphoma Conference, Nirav Shah, MD, discusses innovation and the future development of cell therapies for patients with various types of B-cell malignancies.
At the 2024 Pan Pacific Lymphoma...
08/05/2024
Oncology
Curtis Lachowiez, MD
Videos
Exploring Triplet Therapy for Patients With AML Ineligible for Intensive Induction Chemotherapy
08/05/2024
Curtis Lachowiez, MD, participated in a debate at the 2024 Great Debates and Updates meeting in which he argued in favor of triplet therapy for patients with acute myeloid leukemia who are unable to receive intensive induction chemotherapy.
Curtis Lachowiez, MD, participated in a debate at the 2024 Great Debates and Updates meeting in which he argued in favor of triplet therapy for patients with acute myeloid leukemia who are unable to receive intensive induction chemotherapy.
Curtis Lachowiez, MD,...
08/05/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
Rene Adam, MD, PhD
Conference Coverage
Chemotherapy and Liver Transplantation for Patients With Unresectable Colorectal Liver Metastases
08/02/2024
Rene Adam, MD, PhD, discusses results from the TRANSMET trial which demonstrated that liver transplantation combined with chemotherapy significantly improved survival among patients with unresectable colorectal liver metastases.
Rene Adam, MD, PhD, discusses results from the TRANSMET trial which demonstrated that liver transplantation combined with chemotherapy significantly improved survival among patients with unresectable colorectal liver metastases.
Rene Adam, MD, PhD, discusses...
08/02/2024
Oncology

Interactive Features

Quiz
Osimertinib For Progressive EGFR-Mutated T790M-Negative NSCLC
04/25/2023
How did patients with EGFR-mutated T790M-negative non-small cell lung cancer that had progressed after treatment with TKIs and chemotherapy respond to osimertinib?
How did patients with EGFR-mutated T790M-negative non-small cell lung cancer that had progressed after treatment with TKIs and chemotherapy respond to osimertinib?
How did patients with...
04/25/2023
Oncology
Test Your Knowledge
L858R Mutation by Stage in EGFR-Mutated Lung Cancer
04/13/2023
Is there a difference in L858R mutation rates in EGFR-mutated lung cancer when stratified by stage?
Is there a difference in L858R mutation rates in EGFR-mutated lung cancer when stratified by stage?
Is there a difference in L858R...
04/13/2023
Oncology
Quiz
Are PD-L1 Scores Predictive of TP53 Mutation Rates?
02/13/2023
A study investigated a potential link between PD-L1 scores and TP53 tumor mutation.
A study investigated a potential link between PD-L1 scores and TP53 tumor mutation.
A study investigated a potential...
02/13/2023
Oncology
Quiz
Quiz: Targeted Therapies for EGFR-Mutant Lung Cancer
12/02/2022
What study recently provided an additional 2 years of data to support adjuvant osimertinib as treatment of EGFR-mutant lung cancer?
What study recently provided an additional 2 years of data to support adjuvant osimertinib as treatment of EGFR-mutant lung cancer?
What study recently provided an...
12/02/2022
Oncology
Test Your Knowledge
Quiz: Combination Therapies as Treatment Options for EGFR-Mutated Lung Cancer
11/30/2022
Which combination therapies are currently being evaluated in clinical trials as treatment options for patients with EGFR-mutated lung cancer?
Which combination therapies are currently being evaluated in clinical trials as treatment options for patients with EGFR-mutated lung cancer?
Which combination therapies are...
11/30/2022
Oncology
Quiz
Quiz: Which somatic missense non-synonymous single nucleotide polymorphisms were recently determined to be putative novel rare genetic markers for NSCLC?
10/12/2022
After analyzing a selected pool of oncogenes, which somatic missense non-synonymous single nucleotide polymorphisms did a first-of-its-kind study find to be deleterious in patients with non-small cell lung cancer?
After analyzing a selected pool of oncogenes, which somatic missense non-synonymous single nucleotide polymorphisms did a first-of-its-kind study find to be deleterious in patients with non-small cell lung cancer?
After analyzing a selected pool...
10/12/2022
Oncology
Quiz
Quiz: Amivantamab Outcomes vs Other Real-World Therapies for EGFR-Mutated NSCLC
07/25/2022
In the single-arm CHRYSALIS study, among patients with EGFR exon 20 insertion-mutated advanced NSCLC who progressed after platinum-based chemotherapy, what outcome did not improve when treated with amivantamab vs real-world therapies?
In the single-arm CHRYSALIS study, among patients with EGFR exon 20 insertion-mutated advanced NSCLC who progressed after platinum-based chemotherapy, what outcome did not improve when treated with amivantamab vs real-world therapies?
In the single-arm CHRYSALIS...
07/25/2022
Oncology
Medical
Test Your Knowledge
Quiz: How Does Tisagenlecleucel Affect Activity in ALL?
03/07/2022
True or false: Tisagenlecleucel does not affect activity in young patients with R/R B-cell ALL and adult patients with R/R DLBCL.
True or false: Tisagenlecleucel does not affect activity in young patients with R/R B-cell ALL and adult patients with R/R DLBCL.
True or false: Tisagenlecleucel...
03/07/2022
Oncology
Test Your Knowledge
Quiz: Is This Selective FGFR Inhibitor Safe to Treat Hematologic Malignancies?
02/25/2022
True or false: The FIGHT-101 trial revealed pemigatinib is unsafe for patients with FGFR mutant hematologic malignancies.
True or false: The FIGHT-101 trial revealed pemigatinib is unsafe for patients with FGFR mutant hematologic malignancies.
True or false: The FIGHT-101...
02/25/2022
Oncology
Test Your Knowledge
Quiz: Does This Pan-FGFR TKI Show Long-Term Efficacy?
02/25/2022
True or false: Erdafitinib, a pan-FGFR TKI, showed long-term efficacy for advanced urothelial carcinoma.
True or false: Erdafitinib, a pan-FGFR TKI, showed long-term efficacy for advanced urothelial carcinoma.
True or false: Erdafitinib, a...
02/25/2022
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Addition of Relatlimab to Nivolumab and Chemotherapy Did Not Improve Response Among Patients With Unresectable, Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer
05/23/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 2 RELATIVITY-060 study, the addition of relatlimab to nivolumab and chemotherapy did not improve objective response among patients with unresectable, locally advanced or metastatic gastric or...
According to results from the phase 2 RELATIVITY-060 study, the addition of relatlimab to nivolumab and chemotherapy did not improve objective response among patients with unresectable, locally advanced or metastatic gastric or...
According to results from the...
05/23/2024
Oncology
News
Pembrolizumab Plus Chemotherapy Approved for Patients With HER2-Negative Gastric or Gastroesophageal Junction Cancer
11/17/2023
On November 16, 2023, the FDA granted approval to pembrolizumab plus chemotherapy for the treatment of patients with locally advanced or metastatic HER2-negative gastric or gastroesophageal junction cancer in the first-line setting.
On November 16, 2023, the FDA granted approval to pembrolizumab plus chemotherapy for the treatment of patients with locally advanced or metastatic HER2-negative gastric or gastroesophageal junction cancer in the first-line setting.
On November 16, 2023, the FDA...
11/17/2023
Oncology
News
Trastuzumab Plus Ramucirumab and Paclitaxel Shows Promise Among Patients With Second-Line HER2-Positive, Advanced Gastric or Gastroesophageal Junction Cancer
08/10/2023
In a phase 1b/2 study, trastuzumab plus ramucirumab and paclitaxel showed promise in the second-line setting for patients with HER2-positive gastric or gastroesophageal junction cancer.
In a phase 1b/2 study, trastuzumab plus ramucirumab and paclitaxel showed promise in the second-line setting for patients with HER2-positive gastric or gastroesophageal junction cancer.
In a phase 1b/2 study,...
08/10/2023
Oncology
News
Frontline Tislelizumab Plus Chemotherapy for Patients With Gastroesophageal Squamous Cell Carcinoma
05/23/2023
In a phase 3 trial, tislelizumab plus chemotherapy improved the overall survival of patients with advanced or metastatic gastroesophageal squamous cell carcinoma when compared with placebo plus chemotherapy.
In a phase 3 trial, tislelizumab plus chemotherapy improved the overall survival of patients with advanced or metastatic gastroesophageal squamous cell carcinoma when compared with placebo plus chemotherapy.
In a phase 3 trial, tislelizumab...
05/23/2023
Oncology
News
Zolbetuximab Plus CAPOX Improves Survival in Gastric/Gastroesophageal Junction Cancers
03/25/2023
Zolbetuximab in combination with chemotherapy increases survival in patients with first-line claudin-18.2-positive/HER2-negative locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
Zolbetuximab in combination with chemotherapy increases survival in patients with first-line claudin-18.2-positive/HER2-negative locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
Zolbetuximab in combination with...
03/25/2023
Oncology
News
Potential of Sintilimab Plus Apatinib and Chemotherapy in Gastric or Gastroesophageal Junction Cancer
03/20/2023
In a phase 2 study, sintilimab plus apatinib and chemotherapy demonstrated anti-tumor activity and tolerable safety among patients with gastric or gastroesophageal junction cancer.
In a phase 2 study, sintilimab plus apatinib and chemotherapy demonstrated anti-tumor activity and tolerable safety among patients with gastric or gastroesophageal junction cancer.
In a phase 2 study, sintilimab...
03/20/2023
Oncology
News
Perioperative Nivolumab Plus Ipilimumab for dMMR/MSI-H Gastric/Gastroesophageal Junction Adenocarcinoma
03/02/2023
Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab was associated with high pathological complete response with no unexpected toxicities for patient with dMMR/MSI-H gastric/gastroesophageal junction adenocarcinoma.
Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab was associated with high pathological complete response with no unexpected toxicities for patient with dMMR/MSI-H gastric/gastroesophageal junction adenocarcinoma.
Neoadjuvant nivolumab plus...
03/02/2023
Oncology
News
Adding Atezolizumab to Modified FOLFOX May Improve Response Rates in Gastroesophageal Junction Cancer
02/10/2023
The addition of atezolizumab to modified FOLFOX in the perioperative setting was found to be safe and may improve response rates for patients with gastroesophageal junction cancer.
The addition of atezolizumab to modified FOLFOX in the perioperative setting was found to be safe and may improve response rates for patients with gastroesophageal junction cancer.
The addition of atezolizumab to...
02/10/2023
Oncology
News
Potential of Overlap Guiding Tube-Assisted Method of Esophagojejunostomy for Gastric/Gastroesophageal Junction Cancer
02/08/2023
Study findings reveal the overlap guided tube-assisted method of esophagojejunostomy for gastric/gastroesophageal junction cancer is associated with reduced surgical difficulty vs the conventional method.
Study findings reveal the overlap guided tube-assisted method of esophagojejunostomy for gastric/gastroesophageal junction cancer is associated with reduced surgical difficulty vs the conventional method.
Study findings reveal the...
02/08/2023
Oncology
News
Postoperative Adjuvant Chemotherapy Improves Survival Outcomes for Patients With Gastroesophageal Junction Adenocarcinoma
01/10/2023
According to a study, adjuvant chemotherapy after gastrectomy improved the overall survival and disease-free survival for patients with gastroesophageal junction adenocarcinoma, compared to gastrectomy alone.
According to a study, adjuvant chemotherapy after gastrectomy improved the overall survival and disease-free survival for patients with gastroesophageal junction adenocarcinoma, compared to gastrectomy alone.
According to a study, adjuvant...
01/10/2023
Oncology
News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement